Arkolith/Insider Trading/ATHA/Form 4

Gengos Andrew

CFO and Chief Business OfficerAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Sep 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$725
Net Open-Market Flow
-$725
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 5, 2024Sell(S)1K$0.57$72598K
Sep 3, 2024Grant(A)5K—$099K
May 20, 2024Grant(A)10K$1.34$13K94K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-022987) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Athira Pharma, Inc.

Build

Ask your agent about ATHA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001415889-24-022987"
Ask your agent
Use Arkolith to summarize insider buying and selling at Athira Pharma, Inc.
over the last 90 days and cite the filings.